Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The aim of the prospective study is to determine whether combination/ sequential therapy with
Entecavir, Peginterferon alfa-2b and immunomodulators Granulocyte Macrophage Colony
Stimulating Factor (GMCSF)+vaccine could induce HBsAg loss in chronic hepatitis B patients
with maintained Hepatitis B Virus (HBV) DNA suppression on long-term nucleoside or nucleotide
analogue (NA).